<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780442</url>
  </required_header>
  <id_info>
    <org_study_id>HR#16454</org_study_id>
    <nct_id>NCT00780442</nct_id>
  </id_info>
  <brief_title>D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals</brief_title>
  <official_title>D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In summary, this pilot study will explore the use of an innovative pharmacologic approach to
      the treatment of substance dependence through the facilitation of extinction of response to
      cocaine-conditioned cues in cocaine-dependent individuals. If DCS proves successful in this
      preliminary study, a controlled treatment trial will be planned. This novel approach could
      have implications for the treatment of multiple substance use disorders including
      methamphetamine, marijuana and opiate dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine dependence remains a serious problem in the US today and in spite of two decades of
      intense research, efficacious pharmacotherapeutic treatments have not been identified.
      Cocaine-associated environmental cues can elicit drug craving and exposure to cocaine-related
      cues is likely to be involved in relapse. Emerging data supports the role of glutamate in
      extinction of associative learning in animal models of rear-conditioning and clinical studies
      of exposure treatment for anxiety disorders. A recent study demonstrated DCS acceleration of
      cocaine-induced conditioned place preference in rats. Exploration of DCS in facilitating
      extinction of response to drug-related cues in humans is needed. The proposed study will
      extend these innovative and promising findings from the basic science arena and anxiety
      disorders field in a proof of concept investigation of DCS facilitation of extinction of
      response to cocaine-related cues in a human laboratory paradigm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Craving Scale</measure>
    <time_frame>Immediately following cue exposure</time_frame>
    <description>Scale assess cocaine craving following cocaine cue exposure after two administrations of DCS. Subjects rate craving on a scale from 0-10 with 0 indicating &quot;Not at all&quot; and 10 indicating &quot;Extremely&quot;.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Cocaine Use Disorders</condition>
  <arm_group>
    <arm_group_label>DCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>50 mg DCS</description>
    <arm_group_label>DCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be able to provide informed consent and function at an intellectual
             level sufficient to allow accurate completion of all assessment instruments.

          2. Subjects must meet DSM-IV criteria for current cocaine dependence. Subjects may meet
             criteria for abuse, but not dependence on any other substance within the past 60 days
             with the exception of nicotine. Because of the high comorbidity of cocaine and
             nicotine dependence, excluding nicotine dependence would seriously compromise the
             feasibility of recruitment. Nicotine use immediately prior to the testing session will
             be controlled. Alcohol has also been known to affect HPA function, however to enhance
             recruitment efforts individuals with alcohol dependence or abuse will be included in
             the study if they do not require medically supervised detoxification.

          3. Use of one of the following methods of birth control by female subjects: barrier
             methods (diaphragm or condoms with spermicide or both), surgical sterilization, use of
             an intra-uterine contraceptive device, or complete abstinence from sexual intercourse.

          4. Subjects must live within a 50-mile radius of our research program and have reliable
             transportation.

          5. Subjects must consent to remain abstinent from all drugs of abuse (except nicotine or
             alcohol) for 24 hours immediately prior to the GCRC admission.

          6. Subjects must consent to random assignment to the DCS vs. placebo conditions.

        Exclusion Criteria:

          1. Women who are pregnant, nursing or of childbearing potential and not practicing an
             effective means of birth control.

          2. Subjects with evidence of or a history of significant hematological, endocrine,
             cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease including
             diabetes, as these conditions may affect heart rate or skin conductance measurement.

          3. Individuals with creatinine clearance of 1.2 or greater as DCS is renally excreted.

          4. Subjects with a history of or current psychotic disorder, current major depressive
             disorder, bipolar affective disorder or a severe anxiety disorder as these may impact
             cue reactivity.

          5. Subjects who are unwilling or unable to maintain abstinent from alcohol and other
             drugs of abuse (except nicotine) for 24 hours days prior to the cue procedure.

          6. Subjects meeting DSM-IV criteria for substance dependence (other than nicotine or
             cocaine as appropriate) within the past 60 days.

          7. Subjects currently taking B-blockers, anti-arrythmic agents, psychostimulants or any
             other agents known to interfere with heart rate and skin conductance monitoring.

          8. Known or suspected hypersensitivity to DCS.

          9. Individuals taking medications that could adversely interact with study medications,
             including, but not limited to ethionamide, isoniazid, or amino acid supplements.

         10. Subjects with a history of epilepsy or seizure disorder.

         11. Subjects with significant liver impairment as DCS may increase serum transaminases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee L McRae, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <results_first_submitted>May 3, 2018</results_first_submitted>
  <results_first_submitted_qc>June 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2018</results_first_posted>
  <last_update_submitted>June 6, 2018</last_update_submitted>
  <last_update_submitted_qc>June 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Aimee McRae-Clark</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>substance related disorders</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D-cycloserine</title>
          <description>Participants received DCS prior to cocaine cue exposure sessions.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo prior to cocaine cue exposure sessions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>D-cycloserine</title>
          <description>Participants received DCS prior to cocaine cue exposure sessions.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received placebo prior to cocaine cue exposure sessions.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Craving Scale</title>
        <description>Scale assess cocaine craving following cocaine cue exposure after two administrations of DCS. Subjects rate craving on a scale from 0-10 with 0 indicating &quot;Not at all&quot; and 10 indicating &quot;Extremely&quot;.</description>
        <time_frame>Immediately following cue exposure</time_frame>
        <population>Cocaine dependent individuals</population>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
            <description>Participants received DCS prior to cocaine cue exposure sessions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo prior to cocaine cue exposure sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Craving Scale</title>
          <description>Scale assess cocaine craving following cocaine cue exposure after two administrations of DCS. Subjects rate craving on a scale from 0-10 with 0 indicating &quot;Not at all&quot; and 10 indicating &quot;Extremely&quot;.</description>
          <population>Cocaine dependent individuals</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="3.98"/>
                    <measurement group_id="O2" value="3.13" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-cycloserine</title>
          <description>Participants received DCS prior to cocaine cue exposure sessions.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received placebo prior to cocaine cue exposure sessions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kimber L. Price</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-4847</phone>
      <email>pricekl@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

